Selected Grantee Publications
Antiretroviral Therapy Does Not Reduce Tuberculosis Reactivation in a Tuberculosis-HIV Coinfection Model
Ganatra et al., Journal of Clinical Investigation. 2020.
https://www.jci.org/articles/view/136502
Despite treatment of HIV with antiretroviral therapy (ART), the risk of tuberculosis (TB) reactivation is higher in HIV-infected than HIV-uninfected persons. Researchers used Mycobacterium tuberculosis/SIV-coinfected rhesus macaques to model the impact of ART on TB reactivation due to HIV-induced immunosuppression. ART significantly reduced viral loads and increased CD4+ T-cell counts in blood, spleen, and bronchoalveolar lavage samples, but it did not reduce the risk of SIV-induced TB reactivation during the early phase of treatment. This study offers a translational model for the investigation of TB/SIV coinfection and the evaluation of treatment regimens to prevent TB reactivation in HIV-infected individuals. Supported by ORIP (P51OD011133, P51OD011132) and NIAID.
Epidemiological and Molecular Characterization of a Novel Adenovirus of Squirrel Monkeys After Fatal Infection During Immunosuppression
Rogers et al., Microbial Genomics. 2020.
https://pubmed.ncbi.nlm.nih.gov/32614763/
Adenoviruses frequently cause upper respiratory tract infections, often causing disseminated disease in immunosuppressed patients. A novel adenovirus was identified, squirrel monkey adenovirus 1 (SqMAdV-1), as the cause of a fatal infection in an immunocompromised squirrel monkey (Saimiri boliviensis). A nucleotide polymorphism at the stop codon of the DNA polymerase gene results in a 126 amino acid extension at the carboxy terminus. A single adenovirus variant, SqMAdV-3, has similarity to tufted capuchin (Sapajus apella) adenoviruses. The largest group of adenovirus variants detected, SqMAdV-2.0-2.16, has high similarity (93-99%) to the TMAdV, suggesting that squirrel monkeys may be the natural host of the TMAdV. Supported by ORIP (P40OD010938, R24OD018553), and NIAID.